Literature DB >> 705262

Comparison of the effector cells in human spontaneous cellular cytotoxicity and antibody-dependent cellular cytotoxicity: differential sensitivity of effector cells to in vivo and in vitro corticosteroids.

J E Parrillo, A S Fauci.   

Abstract

The effector cells mediating antibody dependent cellular cytotoxicity (ADCC) and spontaneous cellular cytotoxicity (SCC) in humans have been reported to possess similar characteristics. Multiple cell separation techniques were employed in an attempt to physically separate and distinguish the effector cells in these two types of cellular cytotoxicity. Subpopulations of mononuclear cells obtained by a variety of fractionation procedures which either enriched or depleted monocytes, lymphocytes bearing a receptor for sheep erythrocytes (SRBC), a receptor for complement (CRL) or an Fc receptor for IgG always had similar effects on both ADCC and SCC. Aggregated gamma globulin blockade of Fc receptors produced similar dose-dependent depressions of ADCC and SCC. Despite our inability to physically separate the effector cells of ADCC and SCC, administration of in vivo dexamethasone caused a relative increase in ADCC but a profound decrease in SCC. Furthermore, in vitro dexamethasone in pharmacologic and suprapharmacologic concentrations caused no change in ADCC but significantly decreased SCC. This study demonstrates that although the effector cells cannot be physically separated, ADCC and SCC are differentially sensitive to corticosteroids and are hence functionally distinct either on the basis of different subsets of effector cells with similar surface markers or different mechanisms of cytotoxicity by the same effector cell.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 705262     DOI: 10.1111/j.1365-3083.1978.tb00501.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  22 in total

1.  Role of psychological stress on IBD onset.

Authors:  N Okabe; A Kuroiwa; A Nagayama
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Trichinella pseudospiralis larvae express natural killer (NK) cell-associated asialo-GM1 antigen and stimulate pulmonary NK activity.

Authors:  J Y Niederkorn; G L Stewart; S Ghazizadeh; E Mayhew; J Ross; B Fischer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 3.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

4.  The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease.

Authors:  M Brogan; J Hiserodt; M Oliver; R Stevens; B Korelitz; S Targan
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

Review 5.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

6.  Natural killer cell activity in untreated systemic lupus erythematosus.

Authors:  K Oshimi; M Sumiya; N Gonda; S Kano; F Takaku
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

7.  Immune status in Crohn's disease. 4. In vitro antibody dependent cell mediated cytotoxicity in peripheral blood.

Authors:  I O Auer; E Ziemer
Journal:  Klin Wochenschr       Date:  1980-08-01

8.  Effect of dexamethasone on bovine leukocyte functions and bovine herpesvirus type-1 replication.

Authors:  H B Ohmann; P E Baker; L A Babiuk
Journal:  Can J Vet Res       Date:  1987-07       Impact factor: 1.310

9.  [The influence on PHA-stimulation by inhibition of prostaglandin synthesis in vitro in patients with Hodgkin's disease (author's transl)].

Authors:  H W Pees; G Girmann; J Schwamborn
Journal:  Blut       Date:  1980-04

10.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.